Previous 10 | Next 10 |
home / stock / ucbjy / ucbjy news
UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development - Through this collaboration with Microsoft, UCB seeks to discover and develop medicines faster for people living with severe diseases in immunology and neurology - Microsoft will provide AI ...
UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy - Nile is developing a digital epilepsy care management platform and bringing together data to make the epilepsy journey predictable - UCB invested €25 million ($29...
UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society's Virtual Event AES2020 ATLANTA , Dec. 4, 2020 /PRNewswire/ -- UCB today announced that 15 scientific posters will be presented at the upcoming Ameri...
Specifica Delivers Antibody Platform to UCB to Speed up Development of New Therapeutics PR Newswire SANTA FE, N.M., Dec. 1, 2020 SANTA FE, N.M. , Dec. 1, 2020 /PRNewswire/ -- Specifica, a company revolutionizing antibody discovery, today announced that i...
World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19 - A range of therapeutics will be evaluated for their potential efficacy and safety relative to the condition severity of patients hospitalized with C...
UCB's VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy -- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generali...
UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms - Acquisition of Handl Therapeutics BV augments UCB's existing early gene therapy pipeline with two research programs, a proprietary adeno-associated virus (AAV) capsid tech...
UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020 - C-VIEW study results show CIMZIA® (certolizumab pegol) provided reductions in acute anterior uveitis (AAU) flares in patients with axial spondyloarthritis (axSpA) - C-axSpAnd stud...
Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira® in Moderate-to-Severe Psoriasis Patients - Data from the Phase 3 BE SURE study demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved significantly higher P...
UCB and Aetion Announce Agreement to Enhance Real-World Evidence Generation to Advance Value-Based Contracts UCB will utilize Aetion's analytics platform to align with U.S. payers on treatment outcomes and value PR Newswire NEW YORK, Oct. 7, 2020 NEW YORK , ...
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can ...
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 PR Newswire Patients with non-radiographic axial spondyloarthritis (nr-axSpA) and those with ankylosing spondylitis (AS) treated ...